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The collection of microbes and their genes that exist within and on the human
body, collectively known as the microbiome has emerged as a principal factor in
human health and disease. Humans and microbes have established a symbiotic
association over time, and perturbations in this association have been linked to
several immune-mediated inflammatory diseases (IMID) including inflammatory bowel
disease, rheumatoid arthritis, and multiple sclerosis. IMID is a term used to describe
a group of chronic, highly disabling diseases that affect different organ systems.
Though a cornerstone commonality between IMID is the idiopathic nature of disease,
a considerable portion of their pathobiology overlaps including epidemiological co-
occurrence, genetic susceptibility loci and environmental risk factors. At present, it is
clear that persons with an IMID are at an increased risk for developing comorbidities,
including additional IMID. Advancements in sequencing technologies and a parallel
explosion of 16S rDNA and metagenomics community profiling studies have allowed
for the characterization of microbiomes throughout the human body including the gut,
in a myriad of human diseases and in health. The main challenge now is to determine
if alterations of gut flora are common between IMID or, if particular changes in the gut
community are in fact specific to a single disease. Herein, we review and discuss the
relationships between the gut microbiota and IMID.
Keywords: microbiome, systems microbiology, chronic immune mediated inflammatory diseases, metagenome,
dysbiosis
INTRODUCTION
Immune-mediated inflammatory disease (IMID) is a term used to define a group of clinically
heterogeneous, ostensibly unrelated disorders that are recognized to share common pathogenic
mechanisms. Most IMID are highly prevalent in well-developed industrialized countries; in
Western populations the prevalence of IMID is approximately 5–8% (Bayry and Radstake, 2013)
and encompasses over 100 different clinical diseases including inflammatory bowel disease (IBD),
multiple sclerosis (MS), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus
erythematosus (SLE), and psoriasis/psoriatic arthritis.
Knowledge of the etiopathogenic mechanisms of IMID remains limited but these diseases are
thought to arise secondary to a complex interplay between environmental and genetic factors.
The rise in IMID prevalence in developed countries in the latter half of the 20th century
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implies that environmental determinants play a significant role
in disease onset. Numerous environmental factors have been
proposed to be important in the emergence of IMID including
hygiene, socioeconomic status, cigarette smoking, diet, antibiotic
usage, vitamin D, hormones, appendectomy, excess alcohol,
and microbial exposure (Ananthakrishnan, 2015; Belbasis et al.,
2015), but whether any of these factors are causal in IMID has yet
to be established.
Immune-mediated inflammatory disease also share a
considerable portion of their heritable etiology. This is evident
through familial clustering of multiple IMID, epidemiological
co-occurrence and a similar efficacy of therapeutics directed at
specific biologic loci across some diseases (Somers et al., 2006;
Diaz-Gallo and Martin, 2012), which taken together, suggest that
genetic factors predispose persons to IMID. The best-known
genetic factor of IMID is the human leukocyte antigen (HLA)
haplotypes (Wu et al., 2015). Moreover, genome-wide association
studies have identified associations with more than 200 rare
or common non-HLA variants (Wu et al., 2015) although
known allelic variants account for a relatively low risk explaining
20–50% of disease heritability (Parkes et al., 2013; Sorrentino,
2014).
IMMUNE-MEDIATED INFLAMMATORY
DISEASE COMORBIDITY
Immune-mediated inflammatory disease are defined by the
principle organ system that is affected [the gastrointestinal
tract in IBD, the synovium in RA and the central nervous
system (CNS) in MS]; however, they are associated with
comorbidities that extend beyond the primary target organ. In
this regard, comorbidities that present in persons with IMID
greatly contribute to the burden of disease and quality of
life. IBD for example, frequently manifests with extra-intestinal
complications in up to 50% of cases and covers a broad clinical
spectrum affecting nearly every organ system (Harbord et al.,
2016). Erythema nodosum and pyoderma gangrenosum of skin,
ocular uveitis and episcleritis, primary sclerosing cholangitis, and
arthritides, such as pauciarticular and polyarticular peripheral
arthritis and seronegative spondyloarthropathy are among the
more common extra-intestinal diseases that may coexist in
IBD (Harbord et al., 2016). Rarely, a number of neurological
complications including peripheral neuropathy, myopathy, and
demyelinating disorders may occur in persons with IBD.
Comorbidities are not specific to IBD; persons with other IMID
often present with a number of additional clinical disorders
including risks for osteoporosis, venous thromboembolic disease
and ischemic heart disease (Bernstein et al., 2000, 2001a, 2008).
It is well established that in comparison to the general
population, IMID patients are at greater risk for the development
of another IMID-related condition. Weng et al. (2007) examined
the co-occurrence of IBD with other IMID (asthma, psoriasis,
type 1 diabetes (T1D), RA, MS, SLE, vitiligo, autoimmune
thyroiditis, and chronic glomerulonephritis). The authors
reported 17% of IBD patients and 10% of persons without
IBD were diagnosed with at least one additional IMID. Persons
with IBD had significantly increased odds pertaining to the
development of asthma [odds ratio; OR 1.5, 95% confidence
interval (CI) 1.4–1.6], psoriasis (OR 1.7, 95% CI 1.5–2.0), RA
(OR 1.9, 95% CI 1.5–2.3), and MS (OR 2.3 95% CI 1.6–3.3).
These results have been corroborated by other studies that
add further credence to the validity of the phenomenon of
IMID co-occurrence (Bernstein et al., 2001b, 2005; Cucino and
Sonnenberg, 2001; Cohen et al., 2008; Marin-Jiminez et al., 2014;
Vanaclocha et al., 2015).
An idiopathic etiology represents a pivotal commonality
of IMID, though the clinical, epidemiological, genetic,
and environmental links between IMID combined with the
preeminent association between IBD and the gut microbiome
has laid the foundation for studies evaluating the gut microbiome
in IMID. Intriguingly, recent research suggests there are striking
findings to support the gut microbiome as playing an important
function in the etiopathogenesis of several IMID. Herein, we will
review the current state of the knowledge regarding changes in
the gut microbiome of the more common IMID, including IBD,
MS, RA, AS, SLE, psoriasis, and psoriatic arthritis.
GUT MICROBIOME: AN OVERVIEW
Knowledge of the role of commensal microbes that inhabit
mucosal surfaces of the human body and their role in health and
disease is increasing at a remarkable rate. The term “microbiota”
refers to the population of microbes at a particular anatomical
niche and “microbiome” refers to the collective genes encoded by
all microbes of that particular niche. The human gastrointestinal
tract comprises approximately 1014 bacterial microbes and
amounts to a biomass of approximately 2 kg (Qin et al., 2010).
It has been assumed for some time that there are roughly
10 times as many microbes as there are eukaryotic cells in
the human body, but recent support proposes the ratio for
microbial to human cells is 1.3:1 (Abbott, 2016). The bacteria
of the gut belong to more than 1000 different species encoding
more than 3 million bacterial genes (microbiome) exceeding the
number encoded by the human genome by 150-fold (Qin et al.,
2010).
The study of the gut microbiome cannot be separated
from its environmental context; host genetics, nutrition, the
environment, geographical location, early microbial exposures,
and other factors profoundly impact the microbiome of
the healthy human gut. Extensive sampling of the human
microbiome has revealed that although the diversity and
abundance of microbial communities of particular niches vary
widely both within and among individuals (Huttenhower et al.,
2012), the functional repertoire of the healthy microbiome,
including the gut, is relatively stable regardless of the microbe
composition. A microbiome becomes more stable in adulthood,
which subsequently changes in the elderly (Claesson et al.,
2012). However, there are temporal variations within a healthy
individual’s microbiome that can occur even over a short period
of time (David et al., 2014).
The healthy human gut is dominated by the presence of
four bacterial phyla: Bacteroidetes, Firmicutes, Actinobacteria,
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and Proteobacteria with Bacteroidetes and Firmicutes accounting
for a large majority of endemic bacteria in the gut (Tap
et al., 2009). Within the healthy human gut, the phylum
Firmicutes are divided into two major classes of Gram-
positive bacteria: Bacilli and Clostridia (primarily Clostridium
cluster IV and Clostridium XIVa). The Bacteroidetes are
Gram-negative bacteria, of which the Bacteroides represents
one of the most abundant genera in the gut (Huttenhower
et al., 2012). Considerable diversity of bacterial species exist
within a normal gut; recent studies have recognized common
core subsets within the microbiome that are relatively stable
throughout large populations and that can even persist in
an individuals’ gut for their entire adult life (Faith et al.,
2013).
There is a clear spatial distribution of microbes within the
gastrointestinal tract with diversity increasing from the stomach
to the colon, and it is at the terminal ileum where prevalent
species change from aerobes to anaerobes (Mondot et al., 2013).
Within the gut itself, there is a significant difference in microbial
populations on mucosal surfaces compared to within the lumen
(Li et al., 2015). Microbes at the mucosal surface are in closer
proximity to the intestinal epithelium and may have a greater
influence on the immune system whereas luminal/fecal microbes
might be more essential for energy and metabolic interactions.
This is relevant since many studies of the gut microbiota
use fecal material for community profiling and thus may not
adequately reflect the totality of viable microbes within the
gut.
Under normal physiological conditions, the human gut
microbiota is a homeostatic ecosystem with several vital
functions and interrelationships important to host health
including food digestion, development of the host immune
system and intestinal epithelial barrier and protection against
pathogens (Shreiner et al., 2015). Disruption of this equilibrium
can result in dysbiosis and increase risk of disease. Gut
dysbiosis refers to an altered composition of intestinal microbial
populations and is thought to provide continuous immunological
stimulation leading to immune response anomalies in numerous
IMID. Altered community composition has been established
in a number of gastrointestinal diseases: IBD, celiac disease,
irritable bowel syndrome, functional dyspepsia, antibiotic-
associated diarrhea, tropical enteropathy, and others (Brown
et al., 2015; Keely et al., 2015; D’Argenio et al., 2016; Distrutti
et al., 2016; Larcombe et al., 2016). Accumulating evidence
proposes that dysbiosis of the intestinal microbiota is not
limited to gastrointestinal diseases thereby suggesting that
gut bacteria can affect the systemic immunological response.
A number of studies have investigated gut dysbiosis in relation
to obesity, diabetes, chronic periodontitis, vaginosis, atopic
diseases, non-alcoholic steatohepatitis, Alzheimer’s disease,
and others (Daulatzai, 2014; Adams and Morrison, 2016;
Blasco-baque et al., 2016; Johnson and Ownby, 2016).
While a breakdown in the equilibrium of the intestinal
milieu may be widely recognized, perturbations surrounding
biological mechanisms driving dysbiosis exist and it is unclear
whether dysbiosis manifests as a cause or consequence of
disease.
MICROBIOME AND IMMUNITY LINK
The link between the gut microbiome and host immunity
involves a bidirectional relationship between microbes and
the host innate and adaptive immune system. The balance
between pro- and anti-inflammatory mechanisms is critical
for gut immune homeostasis and is directly affected by the
commensal microbial communities of the gut. For example,
in mice, segmented filamentous bacteria (SFB) promote the
accumulation of pro-inflammatory T helper 1 (Th1) and Th17
cells in the small intestine (Gaboriau-Routhiau et al., 2009).
Anti-inflammatory responses are facilitated by the generation
of regulatory T cells (Treg cells) through short-chain fatty
acid (SCFA) production (Arpaia et al., 2013). Similarly, studies
report retinoic acid (Mucida et al., 2007), bacteria belonging
to the Clostridium cluster IV and XIVa (Atarashi et al., 2013),
polysaccharide A of Bacteroides fragilis (Round and Mazmanian,
2010) and Faecalibacterium prausnitzii (Qiu et al., 2013) to
promote the accumulation of Treg cells. Hence, microbes and
metabolites in the gut are essential in maintaining immunological
equilibrium. And it is suspected that perturbations of the
gut microbiota disrupt this balance primarily affecting the gut
mucosa and also the systemic immune response. A ‘leaky
gut’ characterized by increased gut permeability, microbial
imbalance, and impaired mucosal immunity has been identified
to precede the development of IMID. Figure 1 shows a schematic
illustration of the interaction between the immune system and
gut microbiota in IMID.
GUT MICROBIOTA IN
IMMUNE-MEDIATED INFLAMMATORY
DISEASES
Inflammatory Bowel Disease (IBD)
The two main clinical phenotypes of IBD are Crohn’s disease
(CD) and ulcerative colitis (UC). CD is a transmural disease
characterized by deep ulcerations distributed in a skipped pattern
that can affect the gastrointestinal tract anywhere from the
mouth to the anus, though the terminal ileum is most frequently
affected. In contrast, UC demonstrates continuous, superficial
inflammation (of the mucosa and submucosa) involving the
rectum and extending proximally to the cecum.
At present, not only have numerous candidate pathogens
(adherent invasive E. coli (AIEC), Bacteroides fragilis,
Clostridium difficile, Mycobacterium avium ssp. paratuberculosis,
Yersinia enterocolitica, Listeria monocytogenes, Salmonella,
Campylobacter) been implicated in disease onset and/or
perpetuation (Becker et al., 2015), but over 400 complex
microbiome surveys have been conducted to identify the totality
of microbes in the IBD gut and precisely how the IBD gut
differs from that of a healthy person. Indeed, advances in
culture-independent sequencing and bioinformatics analyses in
recent years have provided tremendous insight into the structure
and function of the gut microbiota. Though patterns of gut
dysbiosis are inconsistent among published studies, partly owing
to specimen type (stool versus biopsy) or analysis methods,
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FIGURE 1 | Role of the gut microbiome in the pathogenesis of IMID.
Enterocytes (via recognition of microbe-associated molecular patterns by
Toll-like receptors) and M cells (transcytosis) communicate microbial dysbiosis
to the mucosal immune system. Gut dysbiosis, in combination with a
reduction of SCFA can shift the Treg-Th17 balance toward inflammation
through Th17 expansion. Several pro-inflammatory cytokines are released in
the lamina propria (LP) including IL-6, IL-17, IL-21, IL-23, and IFN-γ. The
inflammatory state enhances intestinal permeability through expression of tight
junction proteins including occludins and claudins and may lead to microbial
translocation and enhanced antigen exposure in the LP. Activated T cells, B
cells and dendritic cells (DC) travel to the mesenteric lymph nodes (MLN) via
(Continued)
FIGURE 1 | Continued
lymphatic vessels. Antigen presentation by DCs to T cells occurs and B cells
differentiate toward plasma cells. Activated B cells, Th17 cells, and
antibody-producing plasma cells enter circulation. B cells may be stimulated
to differentiate toward autoantibody producing plasma cells if exposed to
mimicry antigen in LP or MLN. Increased Th17 cells and presence of
autoantibodies are the result of the microbiota induced pro-inflammatory
state. Figure adapted from van der Meulen et al. (2016) with permission and
modified.
studies surveying the gut microbiome in persons with IBD have
consistently demonstrated perturbations of the structure and
function of the microbiome.
Studies frequently document an overall reduction of diversity,
the total number of species in a community. In fact, data
from the MetaHIT consortium suggest that persons with IBD
harbor on average 25% fewer microbial genes than healthy
persons (Qin et al., 2010). Diversity is reduced in the fecal
and mucosal microbiomes of IBD (Manichanh et al., 2006;
Lepage et al., 2011) and has also been documented among
monozygotic twins discordant for CD (Dicksved et al., 2008).
Decreased diversity has been attributed to shifts in the abundance
of the Firmicutes, and more specifically the Clostridium leptum
and C. coccoides group (Manichanh et al., 2006). Likewise,
utilizing a custom phylogenetic microarray Kang et al. (2010)
reported some bacteria belonging to the Firmicutes phylum
including Eubacterium rectale of the Lachnospiraceae and
Ruminococcus albus, R. callidus, R. bromii, and F. prausnitzii
of the Ruminococcaceae were 5- to 10-fold more abundant in
healthy persons compared to CD.
The gut microbiome was recently characterized according to
the three most dominant phenotypes of CD: inflammation of
the colon, the terminal ileum, or both (Table 1) (Naftali et al.,
2016). The authors demonstrated ileal and colonic CD sustain
distinct microbiome patterns. For example, ileal CD samples were
richer in Escherichia (Enterobacteriaceae) and disease activity
correlated with Fusobacterium abundance whereas colonic CD
had higher levels of Faecalibacterium and two unidentified genera
of the Clostridiales and Ruminococcaceae. The variance in CD
microbiome patterns suggests that different mechanisms might
underlie the two major clinical manifestations of CD. Recently,
de Meij et al. (2015) described the gut microbiome composition
in active new-onset pediatric CD compared with 3 months
following initiation of treatment. At baseline, a greater diversity
of Proteobacteria and a lower abundance of Bacteroidetes were
observed in CD compared to controls. And upon clinical
remission, the microbiota profile of CD seemed to shift to a
profile similar to the control population.
The largest study to date related to the mucosal-associated
microbiota and new-onset CD conducted by Gevers et al. (2014)
included 468 children and adolescents (<17 years) with newly
diagnosed CD and a control group of 229 persons with non-
inflammatory conditions of the gastrointestinal tract. Mucosal
and fecal samples were obtained prior to the initiation of
treatment in subjects with a spectrum of disease phenotypes
based on severity, location (terminal ileum and rectum) and
behavior. Overall, disease status strongly correlated to increases
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TABLE 1 | Current studies investigating the role of the gut microbiota in IMID patients.
IMID Subjects Comments Reference
IBD Thirty-one patients with ileal,
ileocolic, and colon-restricted CD
Distinct microbiota profiles observed between ileal and colonic CD: ileal CD richer in
Escherichia and disease activity correlated with abundance of Fusobacterium; increased
abundance of Faecalibacterium, Clostridiales, and Ruminococcaceae in colonic CD.
Naftali et al.,
2016
Sixty newly diagnosed pediatric
CD
Increased diversity of Proteobacteria and decreased abundance of Bacteroidetes in CD at
baseline. Microbiota profile of CD resembled profile of controls upon clinical remission.
de Meij et al.,
2015
Four hundred and sixty-eight
newly diagnosed pediatric CD
Increased abundance of Enterobacteriaceae, Pasteurellaceae, Veillonellaceae,
Fusobacteriaceae and decreased abundance of Erysipelotrichales, Bacteroidales, and
Clostridiales correlates with disease status. Shifts more strongly observed in tissue versus
stool.
Gevers et al.,
2014
Fifteen patients with CD, 21
patients with UC
Bacteroidetes and Fusobacteria more abundant in inflamed CD mucosa versus inflamed
UC. Proteobacteria and Firmicutes more abundant in inflamed UC mucosa.
Faecalibacterium, Bacteroides, and Pseudomonas levels differ between inflamed CD and
UC; 13 genera significantly differed within the non-inflamed mucosa. Non-inflamed UC
mucosa most different from non-IBD mucosa. No variation in taxa when comparing different
gut comparatments within CD or UC.
Forbes et al.,
2016
MS Seven RRMS patients Differences in Firmicutes, Bacteroidetes, and Proteobacteria.
Faecalibacterium decreased in MS. Differences in Bacteroidaceae, Faecalibacterium,
Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales in glatiramer
acetate-treated patients compared to untreated. Vitamin D associated with changes in
Firmicutes, Actinobacteria, and Proteobacteria. Untreated patients had increase in
Akkermansia, Faecalibacterium, and Coprococcus after vitamin D treatment.
Mowry et al.,
2012
Cantarel et al.,
2015
Fifty-three MS patients: 22
untreated; 13 glatiramer acetate
treated; 18 IFN-β treated
Increased Methanobrevibacter smithii in MS. Decreased Butyricimonas and
Lachnospiraceae in untreated MS.
Jhangi et al.,
2014
Twenty pediatric RRMS Increased Escherichia, Shigella, Clostridium. Decreased Eubacterium rectale,
Corynebacterium.
Tremlett et al.,
2015
Fifteen pediatric RRMS IL-17+ T cells positively correlated with overall richness and evenness; inverse correlation
between IL-17+ T cells and Bacteroidetes
Tremlett et al.,
2016a
Seventeen pediatric RRMS Decreased Fusobacteria, increased Firmicutes and Euryarchaeota linked to shorter relapse
time.
Tremlett et al.,
2016b
RA Fifty-one early (≤6 mo) RA Decreased bifidobacteria, Bacteroides fragilis subgroup, Eubacterium rectale – Clostridium
coccoides subgroup, and Bacteroides–Porphyromonas–Prevotella groups
Vaahtovuo et al.,
2008
Fifteen early (≤6 mo) RA Increased Lactobacillus and diversity. Liu et al., 2013
Forty-four new-onset RA; 26
chronic, treated RA; 16 PsA
Increased Prevotella copri in NORA; decreased Bacteroides and beneficial microbes. Sher et al., 2013
Seventy-seven treatment naïve
RA; 17 treatment naïve RA paired
with healthy relatives; 21
DMARD-treated RA
Increased Lactobacillus salivarius; decreased Haemophilus. Metagenomic linkage groups
containing Clostridium asparagiforme, Gordonibacter pamelaeae, Eggerthella lenta,
Lachnospiraceae, Bifidobacterium dentium, Lactobacillus sp., and Ruminococcus lactaris
enriched.
Zhang et al.,
2015
Forty RA Expansion of Actinobacteria (Eggerthella, Actinomyces), Turicibacter, Streptococcus.
Reduced Faecalibacterium. Collinsella correlated with high levels of alpha-aminoadipic acid
and asparagine and IL-17A production. Role of Collinsella in altering gut permeability and
disease severity confirmed in experimental arthritis.
Chen et al., 2016
AS Fifteen AS patients Increased prevalence of sulfate-reducing bacteria. Decreased immunological tolerance to
Bacteroides.
Stebbings et al.,
2002
Nine recent-onset (≤48 mo)
TNF-inhibitor naïve AS patients
Increased diversity, Lachnospiraceae, Ruminococcaceae, Rikenellaceae,
Porphyromonadaceae, and Bacteroidaceae; decreased Veillonellaceae and Prevotellaceae
Costello et al.,
2015
(Continued)
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TABLE 1 | Continued
IMID Subjects Comments Reference
SLE Twenty SLE patients in remission Decreased Firmicutes/Bacteroidetes ratio. Reduction of Lachnospiraceae and
Ruminococcaceae, enrichment of Bacteroidales.
Hevia et al., 2014
Psoriasis/
PsA
Fifteen patients with psoriasis of
the skin; 16 PsA
Reduced diversity. Coprococcus decreased in psoriasis and PsA. Akkermansia,
Ruminococcus, Pseudobutyrivibrio decreased in PsA.
Scher et al., 2015
Twenty-nine psoriasis; 31 IBD; 13
concomitant psoriasis and IBD
Lower abundance of F. prausnitzii and higher abundance of E. coli Eppinga et al., 2015
in the abundance of the Enterobacteriaceae, Pasteurellaceae,
Veillonellaceae, and Fusobacteriaceae and a decrease in the
abundance of Erysipelotrichales, Bacteroidales, and Clostridiales.
Importantly, the alterations described were more strongly
observed in tissue samples with weaker correlations observed
in stool, implying a less dramatic shift in the luminal
microbiota regardless of disease presence. The authors also
demonstrated that microbiota profiles at time of diagnosis
could be predictive for future disease outcomes; abundant
levels of Fusobacterium and Haemophilus positively correlated
with the pediatric CD activity index whereas levels of
Enterobacteriaceae were negatively correlated. Furthermore, the
microbiome composition between terminal ileal and rectal
mucosal specimens were determined to be less different than
differences observed between tissue and stool. Our group
has recently reported similar observations of a somewhat
homogenous gastrointestinal tract (using mucosal biopsies from
the ileum, cecum, mid-colon, and rectum) in terms of microbe
content and abundance within CD and UC cohorts (Forbes
et al., 2016). We also explored the presence and absence
of inflammation as an influencing factor on microbiome
composition; shifts in microbe abundance comparing the
inflamed mucosa between CD and UC were observed but these
shifts were more dramatic in the non-inflamed mucosa between
CD and UC.
Microbes Enriched or Reduced in
Inflammatory Bowel Disease
Bacteroides is the most dominant genus in Western microbiotas
and can both positively and negatively affect the host (Wexler,
2007). Generally, while the overall abundance of the order
Bacteroidales is increased in IBD, in certain circumstances
particular species may be reduced; Parabacteroides distasonis
is significantly decreased in inflamed IBD mucosa (Zitomersky
et al., 2013). Pathogenic bacteria including E. coli, and
Shigella, and others such as Rhodococcus and Stenotrophomonas
maltophilia are increasingly observed in IBD (Knösel et al., 2009;
Guerrero et al., 2015; Jensen et al., 2015). Other pathobionts
with potential roles in the disease course include Prevotellaceae,
C. difficile, Klebsiella pneumoniae, Proteus mirabilis, and
Helicobacter hepaticus.
The relative abundance of the Enterobacteriaceae in persons
with IBD (Kolho et al., 2015) and mouse models of IBD (Nagao-
Kitamoto et al., 2016) is increased. Much research has focused on
the role of E. coli, specifically AIEC, in IBD etiology; AIEC strains
have been isolated from ileal-involving CD tissue (Darfeuille-
Michaud et al., 2004) and the genera Escherichia and Shigella
(indistinguishable by 16S analysis) are highly enriched in patients
with IBD and this enrichment was more pronounced in mucosal
samples versus stool samples (Petersen et al., 2015). It has
also recently been demonstrated that a Western diet induces
a shift in microbiome composition increasing the susceptibility
to AIEC infection (Agus et al., 2016). AIEC possess the
capability to invade enterocytes, replicate within macrophages
and induce granuloma formation in vitro (Martinez-Medina and
Garcia-Gil, 2014), and though AIEC strains may be present
within a healthy gut, they do not have the ability to adhere
to ileal enterocytes. Therefore, colonization of the inflamed
ileum provides a preferential environment for these microbes
to influence the disease course. It has also been shown that
the anti-inflammatory drug, mesalamine, used for IBD therapy,
decreases gut inflammation and correlates with a reduction of
Escherichia/Shigella abundance (Morgan et al., 2012).
Fusobacterium species are members of the normal oral
and gut microbiota in humans; however, particular species
(adherent, invasive, pro-inflammatory) are recognized as
opportunistic pathogens in CD and UC. The relative abundance
of Fusobacterium is increased in mouse models and the colonic
mucosa of IBD; Strauss et al. (2011) isolated Fusobacterium
species from 63.6% of patients with IBD versus 26.5% of healthy
controls. Moreover, 69% of all Fusobacterium isolated from IBD
patients were identified as F. nucleatum and strains isolated from
the IBD inflamed mucosa were more invasive in a Caco-2 cell
invasion assay than strains isolated from the healthy mucosa of
IBD or the control group (Strauss et al., 2011). Fusobacterium
species have also been linked to colorectal carcinoma (Mima
et al., 2015) and interestingly, IBD is a recognized risk factor for
colorectal carcinoma (Lutgens et al., 2015).
The reduction of particular commensal microbes and a
concomitant loss of their protective function possibly have a
substantial impact on the course of disease. The ability of
commensal bacteria to produce SCFA including butyrate, acetate
and propionate via dietary fiber (a prebiotic) fermentation is a
key benefit to the human gut. SCFA are a primary source of
energy for colonic epithelial cells and have recently been shown
to mediate homeostasis of colonic regulatory T cell populations
(Smith et al., 2013). The abundance of Faecalibacterium of
the Ruminococcaceae family is reduced in IBD (Lopez-Siles
et al., 2015). F. prausnitzii is an anti-inflammatory commensal
bacterium and produces the SCFA butyrate. F. prausnitzii
administration in mouse models has been shown to reduce
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inflammation and secondly, a reduction in the abundance of
F. prausnitzii has been linked to postoperative disease recurrence
in ileal CD (Sokol et al., 2008). The abundance of other
SCFA producers including the Leuconostocaceae, Odoribacter
splanchnius, Phascolarctobacterium, and Roseburia are reduced
in IBD (Morgan et al., 2012; Machiels et al., 2014). Roseburia
hominis, in particular, inversely correlates to UC disease activity
and duration (Machiels et al., 2014) and has been described as
an acetate user and butyrate producer and is therefore dependent
on other SCFA producers (Duncan et al., 2002). Alterations of
these bacterial populations and concurrent variability of SCFA
production may have profound consequences on host regulatory
mechanisms of inflammation, though studies haven’t established
causality.
Multiple Sclerosis (MS)
Multiple sclerosis is a chronic inflammatory demyelinating
disorder of the CNS. The cause of disease is not entirely
understood, but both genetic and environmental components are
involved in disease susceptibility (Dendrou et al., 2015). Though
the CNS was originally regarded as an immune-privileged
compartment, it is now recognized that immune cells survey the
CNS regularly (Zhang et al., 1994); in MS and related neurological
diseases there is an enrichment of autoreactive immune cells
targeting elements of the CNS (myelin in MS). The discovery
that gut microbes can produce neurotransmitters that can in turn
influence the enteric nervous system and ultimately the CNS has
led to the notion of the microbiota-gut-brain axis (Wang and
Kasper, 2014).
Research investigating the role of the gut microbiome in
experimental autoimmune encephalomyelitis (EAE), an animal
model of MS, suggests a relationship between the gut microbes
and development of MS. Ochoa-Repáraz et al. (2009) utilized a
cocktail of oral antibiotics (ampicillin, vancomycin, neomycin
sulfate, and metronidazole) to disrupt the gut microbiome
of mice prior to induction of EAE. The authors reported
oral antibiotic treatment significantly decreased gut bacterial
populations and reduced the onset and severity of EAE. The
reduced severity of EAE was ascribed to decreased levels of
pro-inflammatory cytokines and chemokines and elevated levels
of anti-inflammatory cytokines including IL-10 and IL-13; IL-
10-producing Foxp3+ Treg cells were shown to accumulate in
mesenteric and cervical lymph nodes and seemed to mediate
the severity. Additionally, adoptive transfer of Foxp3+ Treg
cells to naïve recipients conferred protection against disease.
Furthermore, disease was observed among antibiotic treated mice
with reduced CD25+ T cells. In contrast, in the absence of
antibiotics, disease was exacerbated in CD25+-deficient mice.
This implies regulatory populations other than Th1, Th17, or
Treg cells may be pertinent to conferring protection against
disease. An additional study in mice treated with oral antibiotics
suggests a role for IL-10 producing CD19+ B cells (Ochoa-
Repáraz et al., 2010a). Adoptive transfer from antibiotic treated
mice to naïve recipient mice reduced severity of disease and
this protective effect was attributed to shifting the immune
response from a pro-inflammatory Th1/Th17 response to an
anti-inflammatory Th2 response.
Lee et al. (2011) demonstrated disease protection in EAE
is associated with reduced levels of the pro-inflammatory
cytokines IFN-γ and IL-17A, both of which play critical roles
in the development of EAE. Increased Foxp3+ Treg cells in
the peripheral lymphoid tissues and the CNS were observed
in germ-free mice. The authors further reported that SFB
monocolonization of mice restored disease and examination
of CNS tissues showed enhanced invasion by Th1 and Th17
cell populations. Using a relapsing-remitting mouse model
(SJL/J) of spontaneously developing EAE, Berer et al. (2011)
reported that the commensal gut microbiota is essential in
triggering immunological processes that lead to relapsing-
remitting autoimmune disease and that myelin-specific CD4+
T cells were driving factors of autoimmunity. Additionally,
the activation of autoantibody-producing B cells was shown to
be dependent upon the availability of the myelin autoantigen
(specifically, MOG) and the gut microbiota.
The ability of probiotics to modify the clinical outcome of
murine EAE has also been investigated. Prophylactic treatment
with Lactobacillus paracasei and L. plantarum DSM 15312
was shown to induce Treg cells in mesenteric lymph nodes
and enhance production of TGFβ1 whereas increased serum
IL-27 levels were observed with L. plantarum DSM 15313
(Lavasani et al., 2010). Interestingly, administration of each
strain independently was unsuccessful therapeutically whereas
combinatorial administration suppressed disease perpetuation
and reversed clinical signs of EAE. Disease amelioration was
attributed to attenuation of the pro-inflammatory Th1/Th17
response and induction of Treg cells through elevated IL-10
levels. Comparably, an additional probiotic, Bifidobacterium
animalis demonstrated similar suppressive effects (Ezendam
et al., 2008). It has also been reported that some probiotic
bacteria, notably L. casei Shirota, enhanced the duration of EAE
(Ezendam and van Loveren, 2008); however, this was refuted
in a subsequent study that determined neither L. casei Shirota
nor B. brevis strain Yakult exacerbates EAE (Kobayashi et al.,
2010). Prophylactic administration of five probiotics (IRT5;
L. casei, L. acidophilus, L. reuteni, B. bifidum, and Streptococcus
thermophilus) prior to disease induction significantly suppressed
development of EAE (Kwon et al., 2013) whereas treatment with
IRT5 to EAE delayed disease onset. Prophylactic and therapeutic
efficacy of IRT5 probiotics was ascribed to inhibition of Th1
and Th17 responses and induction of IL-10-producing and/or
Foxp3+ Treg cells.
To further explore how the microbiome affects EAE
susceptibility and severity, the role of particular commensals
or their products was considered. Ochoa-Repáraz et al. (2010b)
investigated oral treatment of mice with polysaccharide A
(PSA) of B. fragilis. In PSA treated mice, EAE severity was
decreased relative to untreated mice and decreased numbers
of Th1 and Th17 cells were reported in the EAE brains
of PSA-treated mice. Moreover, lymphocytes isolated from
the cervical lymph nodes of PSA-treated mice reportedly
produced more IL-10 and less IL-17 and IFN-γ when stimulated
with myelin oligodendrocyte glycoprotein (induction of EAE).
Phosphorylated dihydroceramides, lipids derived from the oral
commensal P. gingivalis, demonstrated enhanced EAE severity
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through induction of DC IL-6 secretion in a TLR2-dependent
manner and a subsequent decrease in Foxp3+ Treg cell
populations (Nichols et al., 2009). A recent study demonstrated
oral administration of a Lactococcus lactis strain that produces
heat shock protein-65 prevented development of murine EAE;
the suppressive effect was ascribed to elevated IL-10 and reduced
IL-17 production (Rezende et al., 2013).
Little is known about what impact the gut microbiome
may have on human MS etiopathogenesis; gut microbiome
studies are mostly limited to case-control examinations in
persons with MS. Mowry et al. (2012) reported relapsing-
remitting MS (RRMS) patients to have differing levels of
Firmicutes, Bacteroidetes, and Proteobacteria, and that shifts
in the abundance of Firmicutes was more dramatic in patients
treated with glatiramer acetate, an immunomodulator drug.
Comparatively, vitamin D treatment was associated with changes
in Firmicutes, Actinobacteria, and Proteobacteria in RRMS
patients, and increases in Enterobacteria in both RRMS and
healthy controls. Vitamin D has been a main suspect in
MS etiology for some time (Holmøy and Torkildsen, 2016).
The beneficial aspects of vitamin D in the treatment of MS
including exerting anti-inflammatory effects, possible influence
on remyelination and its link to disease activity is widely
accepted and is actively used as a therapeutic (Jarrett et al.,
2014). The mechanism of benefit is unknown but it is plausible
that it has an impact on the gut microbiome. Additional
analysis by the same group revealed that although overlap
of bacterial communities has been observed. Particular taxa
including Faecalibacterium were reported to be lower in persons
with MS (Cantarel et al., 2015). Of note, Faecalibacterium is
considered to be immunosuppressive through production of
the SCFA butyrate. Glatiramer acetate-treated patients showed
differences in microbe composition including Bacteroidaceae,
Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium,
and additional Clostridiales compared to untreated persons.
After vitamin D supplementation, untreated persons with
MS had an increase in Akkermansia, Faecalibacterium, and
Coprococcus. Although these studies are exploratory and future
studies in larger cohorts are needed to confirm these findings,
these results suggest that the microbial communities of the
MS gut are subject to modulation by some drugs commonly
used in the treatment of MS. Jhangi et al. (2014) found
a significant increase in the highly immunogenic Archaea
Methanobrevibacter smithii, which might play a role in
inflammation due to their structural components. Butyricimonas
and Lachnospiraceae, which are butyrate producers with anti-
inflammatory properties, were lower in untreated MS. Tremlett
et al. (2015) explored gut microbiome profiles in pediatric MS;
increases in Escherichia, Shigella, and Clostridium were observed,
and decreases in Eubacterium rectale and Corynebacterium.
Recently, the association between gut community profiles in 15
pediatric RRMS patients and host immunological markers such
as IFN-γ, IL-17, IL-10, CD4+CD25+Foxp3+ Treg were explored
(Tremlett et al., 2016a). The authors reported immune markers
did not differ between RRMS and controls but did observe
divergence in the association between the gut microbiome and
immunological markers. IL-17+ T cells positively correlated with
overall richness and evenness whereas an inverse correlation
between IL-17+ T cells and Bacteroidetes abundance in MS was
reported. Another study reporting on the association between
the gut microbiota composition and relapse risk in pediatric
MS showed a decrease in Fusobacteria, increase in Firmicutes
and the presence of the Archaea Euryarchaeota was associated
with a shorter time to relapse (Tremlett et al., 2016b). Thus far,
current studies indicate that gut dysbiosis is linked with MS.
Common findings include a reduction in the phyla Bacteroidetes
and Firmicutes, which are important for immunoregulation and
production of SCFA.
Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a common systemic autoimmune
disease that manifests in the joints and if untreated can
lead to chronic joint deformity, disability and increased
mortality owing to cardiovascular and other concurrent,
systemic complications. Notwithstanding recent advances in
understanding the pathogenesis of RA (McInnes and Schett,
2011), the etiology remains undefined. Numerous genetic
susceptibility risk alleles have been identified, but are insufficient
to account for disease incidence. Therefore, RA is considered a
multifactorial disease requiring both genetic and environmental
factors for disease onset and/or progression.
Gut bacteria as an autoimmune trigger in RA has been
recognized for decades. Mansson and Colldahl (1965) reported
the majority of RA patients to have an intestinal flora with
increased amounts of Clostridium perfringens type A in their
feces. The patients also showed immune responses with elevated
antibody titers to C. perfringens alphatoxin and positive skin tests.
Ultimately, the elevation of C. perfringens was not specific to RA
but was instead identified in a number of diseases, in particular,
other chronic arthritides. It was later hypothesized that there are
many bacteria involved in the pathogenesis of RA and not just
one bacterium (Gullberg, 1978).
An accumulating body of literature exists to support a
connection between gut bacteria and arthritis or more commonly
referred to as the ‘gut–joint axis’ hypothesis. The groundbreaking
study to identify the pro-arthritogenic role played by intestinal
bacteria was reported by Kohashi et al. (1979) who discovered
germ-free rats developed severe joint inflammation with 100%
incidence in an adjuvant-induced arthritis model as compared to
conventionally raised controls that developed less severe arthritis
and at a modest incidence. This observation suggests that the
gut microbiota may have important immunosuppressive effects.
Other notable early findings supporting gut involvement in RA
include studies reporting either protective or proarthritogenic
roles of E. coli and Bacteroides species when introduced into
germ-free arthritis-prone rats (Kohashi et al., 1985, 1986; Rath
et al., 1996); germ-free HLA-B27 transgenic rats remained
unaffected from inflammatory (intestinal and peripheral) joint
disease (Taurog et al., 1994), and germ-free rats become
susceptible to arthritis –attributed to a loss of T-cell tolerance–
in a streptococcal cell wall-induced rat arthritis model (van
den Broek et al., 1992). More recently, Abdollahi-Roodsaz
et al. (2008) determined arthritis is attenuated in IL-1 receptor
antagonist-knockout (Il1rn−/−) mice (a model whereby mice
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spontaneously develop an autoimmune T-cell mediated arthritis).
Applying gnotobiological methods, the introduction of the
commensal species Lactobacillus bifidus resulted in disease
onset. Development of arthritis in this model was attributed to
an imbalance of Treg-Th17 homeostasis. Additional evidence
comes from a study using the K/BxN T-cell receptor transgenic
model of inflammatory arthritis (Wu et al., 2010). Germ-free
mice did not develop disease, implying the gut microbiota
is critical to the development of arthritis; protection of
arthritis was ascribed to an absence of peripheral Th17 cells.
Interestingly, monocolonization of germ-free K/Bxn mice with
SFB effectively stimulated an autoimmune response thereby
resulting in arthritis; autoimmunity developed as a result of
promoting Th17 cells. Collectively, the above data derived from
germ-free and gnotobiotic experimental animal models imply
that the gut microbiota –particularly in a state of dysbiosis–
is deemed necessary to trigger autoimmunity and consequent
inflammatory arthritis. Moreover, the transition from a ‘normal’
gut microbiota to a state of dysbiosis likely requires a genetic
predisposition.
One of the initial microbiome surveys in RA reported that
persons early in disease course (disease duration ≤6 months)
harbor significantly less bifidobacteria, Bacteroides fragilis
subgroup, bacteria of the Eubacterium rectale – Clostridium
coccoides subgroup and Bacteroides–Porphyromonas–Prevotella
groups in comparison to persons with non-inflammatory
fibromyalgia (Vaahtovuo et al., 2008). Another study specifically
examined the relationship of Lactobacillus to RA (Liu et al.,
2013); the authors identified significantly more Lactobacillus
(10.62 ± 1.72 copies/g) in the RA gut compared to healthy
controls (8.93 ± 1.60 copies/g). Furthermore, an increase in
diversity and bacterial abundance was reported suggesting a
possible relationship between Lactobacillus populations and
disease onset and/or progression of RA. The abundance of
Lactobacillus communities in RA, and other IMID, is relevant
as these microorganisms and others are considered probiotic
microbes that may confer a health benefit to the host. Sher
et al. (2013) identified a strong association between Prevotella
copri with new-onset untreated RA (NORA) and increases in
the abundance of Prevotella corresponded with a reduction of
several beneficial microbes, including the Bacteroides. Moreover,
a negative correlation between the relative abundance of P. copri
and the presence of shared epitope risk alleles was identified,
indicating that the role of P. copri may play a more important
role in persons with a lower load of genetic susceptibility.
Zhang et al. (2015) recently analyzed the fecal, dental and
salivary microbiome from treatment-naïve RA and unrelated
healthy controls, as well as treatment-naïve RA paired with
healthy relatives and DMARD-treated RA patients, representing
the largest RA cohort and most comprehensive metagenomics
analysis to date. The fecal analysis showed that Haemophilus spp.
were depleted and Lactobacillus salivarius was over-represented
in RA, and that more dramatic changes in abundance were
observed in cases of active disease. In contrast, the abundance
of P. copri was detected as a function of RA duration within
the first year. Metagenomic linkage groups comprised of
Clostridium asparagiforme, Gordonibacter pamelaeae, Eggerthella
lenta, and Lachnospiraceae bacterium as well as B. dentium,
Lactobacillus sp., and Ruminococcus lactaris were enriched in
the RA gut. The investigators also showed that the altered gut
microbiome could be used to identify RA patients, correlated
with clinical indices [for example, titers of immunoglobulin
A (IgA), major serum immunoglobulin (IgG), platelet count,
anticyclic citrullinated peptide (anti-CCP) and rheumatoid factor
(RF)], and could be utilized to stratify individuals based on their
therapeutic response with disease-modifying anti-rheumatic
drugs (DMARDs). And functionally, the redox environment and
transport and metabolism of iron, zinc and sulfur were altered
in persons with RA. A newly published study examined the
microbial and metabolite profile in RA (Chen et al., 2016).
RA patients were found to demonstrate a reduced microbial
diversity and this correlated to disease duration and antibody
levels. The gut in persons with RA was characterized by an
expansion of the typically low-abundant phylum Actinobacteria
and a decrease in more dominant phyla. The genera Eggerthella
and Actinomyces of the Actinobacteria and Turicibacter and
Streptococcus of the Firmicutes were significantly expanded in
RA whereas the abundance of Faecalibacterium was significantly
reduced. Moreover, the abundance of Collinsella correlated with
high levels of alpha-aminoadipic acid and asparagine and IL-
17A production. The study also confirmed the role of Collinsella
in altering gut permeability and disease severity in experimental
arthritis.
Ankylosing Spondylitis (AS)
Ankylosing spondylitis belongs to a group of arthritides referred
to as spondyloarthropathies. AS primarily targets the spine and
sacroiliac joints and is characterized by enthesal inflammation.
Disease progression is characterized by excessive bone formation
(ankylosis) and eventually fuses joints, resulting in pain, stiffness,
morbidity, and increased mortality (Thomas and Brown, 2010).
The etiology of AS is unclear although environmental and genetic
associations are considered to play a role. AS has been linked with
the HLA-B27 allele since the 1970s (Schlosstein et al., 1973) and
the recurrence risk among siblings and first degree relatives is
8.2% versus the general population with a risk of 0.1% (Brown
et al., 2000).
Gut involvement in AS has been recognized for decades.
Clinically, between 5 and 10% of persons with AS develop
IBD at some time, and 70% of persons with AS are diagnosed
with subclinical gut inflammation (Mielants et al., 1991).
Relatively few studies have characterized the gut microbiome
as it relates to AS. An early study by Stebbings et al. (2002)
utilizing denaturing gradient gel electrophoresis reported no
discernable differences in microbe populations of stool between
15 AS patients and 15 matched healthy controls as all subjects
had unique and stable community profiles. Further analysis
revealed a higher proportion of AS fecal samples contained
sulfate-reducing bacteria [similar to IBD (Kushkevych, 2014)]
compared to controls and a potential loss of immunological
tolerance to autologous Bacteroides. Newly published evidence
reveals a distinct microbial signature in the terminal ileum:
Costello et al. (2015) recently surveyed the AS gut microbiome
via 16S rRNA sequencing using terminal ileal biopsies from
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9 AS patients and 9 controls. The terminal ileum of AS
showed an enrichment of Lachnospiraceae, Ruminococcaceae,
Rikenellaceae, Porphyromonadaceae, and Bacteroidaceae, a
depletion of Veillonellaceae and Prevotellaceae and an overall
increase in microbe diversity. Although the authors reported a
decreased abundance of Streptococcus and Actinomyces in AS
relative to healthy controls, they did not observe any differences
in bacteria previously suspected to trigger AS, like Klebsiella
species (Ebringer et al., 1977). Moreover, a recent study reported
breast-feeding to induce protective effects on the development
of AS (Montoya et al., 2016); interestingly, nutrition has a major
impact on early microbiome composition and function (Backhed
et al., 2015).
Animal models have demonstrated that gut dysbiosis plays a
significant role in AS. Ankylosing enthesopathy (ANKENT) is
a naturally occurring disease in mice with several parallels to
human AS; in the ANKENT model, mice spontaneously develop
ankylosis and enthesitis of the tarsal joint and ankle. Germ-
free mice failed to develop ANKENT (Rehakova et al., 2000),
however, mice colonized with common gut bacteria Bacteroides,
Enterococcus, Staphylococcus and Veillonella developed joint
disease but not when colonized with probacterium Lactobacillus
(Sinkorova et al., 2008). Lin et al. (2014) characterized cecal
microbiome differences mediated by the presence of the HLA-
B27 gene (HLA-B27/human-ß2m transgenic rats versus wild-
type Lewis rats) via biome representational in situ karyotyping
(BRISK) and 16S rRNA sequencing. The BRISK analysis reported
a higher prevalence of Bacteroides vulgatus in transgenic rats and
16S analysis showed increased abundance of Paraprevotella and
decreased abundance of Rikenellaceae. The authors concluded
that HLA-B27 is associated with a dysbiosis of the cecal
microbiome. Another study by the same group reported an
inflammatory cytokine signature and increased expression of
antimicrobial peptides throughout the post-weaning period
preceded the development of clinical bowel inflammation and
dysbiosis in HLA-B27/ß2m rats (Asquith et al., 2016). Th17
populations were increased in cecal and colonic mucosa and
also, increased Akkermansia muciniphila colonization and IgA
coating of gut bacteria were correlated with HLA-B27 and clinical
arthritis.
Another study explored the influence of bacterial cell
wall components 1,3 ß-glucan (curdlan) or mannan on
spondyloarthritis development. Using SKG mice (BALB/c ZAP-
70W163C-mutants), Ruutu et al. (2012) reported ß-glucan to
trigger spondyloarthritis and CD-like ileitis whereas mannan
triggered spondylitis and arthritis which were T-cell and IL-
23 dependent. The same group compared the responses of
SKG mice (BALB/c ZAP-70W163C-mutants) deficient and wild-
type for Toll-like receptor 4 to curdlan (Rehaume et al.,
2014). Mice were raised under germ-free or specific pathogen
free conditions and some mice were recolonized with altered
Schaedler flora. The study demonstrated inflammation was
present in all cases of curdlan exposure and that incidence and
severity of arthritis/ileitis was dependent on microbiota content
with severity of disease positively correlating with increased
microbiome diversity.
Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus is a multi-system IMID with many
clinical phenotypes and commonly involves the skin, joints,
brain, kidneys, serosal surfaces, blood cells, blood vessels, heart,
and lungs (Goldblatt and O’Neill, 2013). SLE affects persons with
a wide spectrum of symptoms and disease courses including
most frequently constitutional symptoms, malar (butterfly)
rash, arthritis or arthralgia, renal and hematological symptoms
(Goldblatt and O’Neill, 2013). From an immunological point
of view, SLE demonstrates aberrant responses at varying
levels: uncontrolled T-cell differentiation and activation,
abnormal polyclonal B-cell activation and proliferation and
autoantibody production linked to immune complex formation
(Mok and Lau, 2003). It is the B-cell hyperactivity resulting
in the production of several autoantibodies including those
against double-stranded DNA, nucleosomes, phospholipids,
N-methyl-D-aspartate receptor, C1q, and others (Goldblatt
and O’Neill, 2013) that is a key pathological feature of
SLE.
The role of the gut microbiome in SLE is an emerging
field of research. Hevia et al. (2014) recently reported the first
comprehensive characterization of the SLE gut microbiome:
significant decrease in the Firmicutes/Bacteroidetes ratio
was observed, similar to shifts observed in type 2 diabetes
(Larsen et al., 2010) and CD (Manichanh et al., 2006).
The change of Firmicutes/Bacteroidetes abundance in
SLE was attributed to members of the orders Bacteroidales
(Bacteroidetes) and Clostridiales (Firmicutes). Lachnospiraceae
and Ruminococcaceae were positively associated with healthy
controls. Some species of the Lachnospiraceae family like
Roseburia sp. and Butyrivibrio sp. are butyrate producers;
butyrate production in the human gut is highly relevant as
it promotes Treg cell differentiation which can ultimately
suppress pro-inflammatory responses (Singh et al., 2014).
Bacteroides were significantly higher in SLE patients and
Desulfovibrio were significantly reduced. The study also explored
the functionality of the microbiome: glycan degradation
pathways, lipopolysaccharide biosynthesis proteins and oxidative
phosphorylation processes were associated with SLE partly
explained by the increased abundance of Bacteroidetes, and
more specifically Bacteroides. Another study by the same group
performed a metabolome-wide scan of the gut microbiome
(Rojo et al., 2015). The authors observed a slight difference
(0.72% of metabolic mass features) in the gut metabolome but
not in taxa composition and abundance of the gut microbiota.
Cuervo et al. (2015) investigated the influence of dietary
components to the gut microbiome of SLE. Positive correlations
were identified between flavone and Blautia, flavanones, and
Lactobacillus, and dihydrochalcones and Bifidobacterium in SLE;
dihydroflavanols directly associated with Faecalibacterium and
flavanol inversely correlated with Bifidobacterium in healthy
controls.
Several studies utilizing murine models have demonstrated
that gut dysbiosis might in fact be causal in the development
of SLE. The effect of host genetics, sex, age, and dietary factors
was recently investigated in a murine lupus model (Zhang
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et al., 2014). The female to male ratio for SLE is 10:1 and
incidence rates at age 20–29 is highest (Jarukitsopa et al.,
2015). Overall, young, female lupus-prone mice showed an
increase in Lachnospiraceae and Bacteroidetes and a decrease
in Bifidobacteriaceae and Erysipelotrichaceae. Diversity was also
increased and lactobacilli were present in reduced numbers.
The functional profile of lupus-prone mice revealed bacterial
motility and sporulation-related pathways to be enriched.
Retinoic acid as a dietary factor was found to restore
lactobacilli populations, which correlated with reversing SLE
functional pathways and improved symptoms. Additionally, the
gut microbiome of lupus-prone mice differed between sexes;
Lachnospiraceae were overrepresented in females that were
found to correlate to earlier disease onset and/or increased
diseases severity. A recent study assessing the impact of
dietary factors on the development of SLE prone mice revealed
significant differences in gut microbiome composition during
pre-nephritic stages in mice drinking neutral (pH 7.0–7.2) versus
acidic water (pH 3.0–3.2) and that mice drinking acidic water
demonstrated lower levels of SLE-associated antibodies (anti-
dsDNA and anti-nucleohistone), lower immune cell infiltrates in
the kidney, and a slower progression of nephritis (Johnson et al.,
2015).
Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic, inflammatory multi-organ disease, with
a well-characterized and even pathognomonic pathology
primarily manifesting in the skin and frequently the
joints. The pathophysiology is dynamic and multifaceted,
involving a complex interplay between genetics [HLA-
Cw06 allele variant confers strongest susceptibility (Nair
et al., 2006)], environmental triggers and both the innate
and adaptive immune systems. Furthermore, approximately
24% of persons with psoriasis have concurrent psoriatic
arthritis (Prey et al., 2010), a complex disorder involving
peripheral and axial joints, dactylitis, enthesitis, and
psoriasis.
Particular phenotypes of psoriasis have long been clinically
linked to tonsillar infection with group A ß-haemolytic
streptococci (Valdimarsson et al., 1995), and exacerbation
of disease with skin or gut colonization by Staphylococcus
aureus and fungi Candida albicans and Malassezia (Fry and
Baker, 2007), however, studies investigating the correlation of
psoriasis with the microbiome of the skin or gut are in their
infancy. Fahlén et al. (2012) surveyed the cutaneous psoriasis
microbiome via 16S rRNA sequencing. The study demonstrated
that the Proteobacteria phylum was overrepresented and the
abundance of Staphylococci and Propionibacteria was lower
in psoriasis versus control skin. A recent study characterizing
the gut microbiome reported an overall reduction of bacterial
diversity and depletion of multiple (beneficial) gut bacteria in
psoriasis and psoriatic arthritis and that changes in abundance
were more dramatic in psoriatic arthritis (Scher et al., 2015).
Both patient groups showed a decrease in Coprococcus species
whereas psoriatic arthritis showed a reduction of Akkermansia,
Ruminococcus, and Pseudobutyrivibrio. Interestingly, the authors
determined that the gut microbiota profile of psoriatic arthritis is
similar to the profile commonly observed in the IBD gut. Another
study identified an IBD-like decrease of Faecalibacterium
prausnitzii and increase of E. coli adding further support of a
gut-skin axis (Eppinga et al., 2015). Gut dysbiosis in psoriatic
arthritis has been shown to correlate to an increase of secretory
IgA (sIgA) levels and a decrease of receptor activator of nuclear
factor kappa-B ligand (RANK-L) levels within the gut luminal
content (Scher et al., 2015). These results suggest that sIgA and/or
RANK-L may be signs of a gut barrier breach due to dysbiosis
or their possible role of disseminating inflammation to distant
organs.
The Gut Virome in Immune-Mediated
Inflammatory Disease
To date, human microbiome studies have largely focused on
bacterial components of the microbiome, though emerging
data suggest that the viral components of the microbiome
(virome) can have a profound impact on the host. Advances
in sequencing technology and bioinformatics analysis have led
to the discovery of a diverse human gut virome comprised
of eukaryotic viruses and bacteriophages (viruses that infect
bacteria) that outnumber human cells by 100-fold (Mokili et al.,
2012). The functionality of the virome is not well defined
although recent studies suggest the virome does in fact play
an important role. It has been shown that a common enteric
RNA virus, murine norovirus, can replace the beneficial function
of commensal bacteria in germ-free or antibiotic-treated mice
(Kernbauer et al., 2014). Importantly, eukaryotic viruses have
demonstrated an interaction with IBD susceptibility genes to alter
gut microbial populations as demonstrated in studies of mice
carrying mutations in Il-10 (Basic et al., 2014) or Atg16l1 (Cadwell
et al., 2010).
In the absence of disease, gut bacteriophage populations
exhibit significant diversity and are predominated by members
of the Caudovirales or Microviridae (Castro-Mejía et al., 2015).
A number of studies have investigated the role of bacteriophages
with respect to IBD. The abundance of bacteriophages in
mucosal biopsies are significantly increased in CD versus healthy
controls (Lepage et al., 2008), and are also more diverse in
pediatric CD compared to healthy controls (Wagner et al., 2013).
New evidence demonstrates that disease-specific alterations
exist in the gut virome in IBD (Norman et al., 2015). This
study showed that the IBD gut virome is abnormal; the gut
virome richness is increased and a significant expansion of
Caudovirales was observed in both CD and UC, but particular
viromes of CD and UC were disease and cohort specific.
Importantly, the expansion and diversification of the gut virome
was found to be independent from alterations in bacterial
populations.
As virome profiling in health and disease is a relatively new
field, data are currently limited to investigations of IBD. With
numerous viral infections as potential environmental triggers in
IMID, particularly Epstein-Barr virus or cytomegalovirus in MS
(Belbasis et al., 2015) and several other lines of evidence that
indicates a role for viruses, we anticipate future studies will target
the gut virome in other IMID.
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The Gut Mycobiome in
Immune-Mediated Inflammatory Disease
The human fungal microbial populations (mycobiome) are
now appreciated as complex and important for human health.
Research of the mycobiome has only recently begun, particularly
in health and in IBD. Fungal DNA accounts for approximately
0.2% of the mucosa-associated microbiota and 0.3% of the
fecal microbiota (Ott et al., 2008). The fungal constituents
of the healthy human gut have been characterized and
were found to contain Aspergillus, Candida, Cryptococcus,
Penicillium, Pneumocystis, and Saccharomyces (Dollive et al.,
2012). In IBD, the fecal mycobiome was recently reported
to be skewed (Sokol et al., 2016). Specifically, the authors
observed an increased Basidiomycota/Ascomycota ratio, a
reduced abundance of Saccharomyces cerevisiae and an increased
abundance of Candida albicans relative to healthy controls.
The study also explored the relationship between fungal and
bacterial populations and suggests that CD may favor fungi
at the expense of bacteria and that disease-specific inter-
kingdom alterations exist. Mukhopadhya et al. (2014) studied
the mycobiome in newly diagnosed pediatric IBD patients and
found the phylum Basidiomycota to dominate in IBD whereas
Ascomycota dominated in healthy controls. A higher fungal
diversity has also been reported in CD but no disease-specific
fungal species were reported in either CD or UC (Ott et al.,
2008). Fungal abundance has also been linked to diet (Hoffmann
et al., 2013); Candida positively associated with carbohydrate
consumption and negatively associated with saturated fatty acid
levels whereas Aspergillus negatively associated with SCFA levels
in a carbohydrate-rich diet. Interestingly, anti-Saccharomyces
cerevisiae antibodies (ASCA) have a role in diagnosis, disease
phenotype and prognosis in CD (Russell et al., 2009).
Other domains of microorganisms including the archaea,
fungi, or viruses are increasingly being recognized to have
important functions in host health. However, in terms of studying
the microbiota, research has been very bacteria-centric, as only a
limited number of studies have investigated the micro-eukaryotes
or viral components in IMID.
Therapeutic Manipulation of the Gut
Microbiome
The gut microbiota is increasingly being recognized as an
attractive target for therapeutic intervention. Exposure to
particular antibiotics is a known risk factor for development
of some IMID, however, antibiotics may also impact on IMID
disease course by reducing concentrations of luminal gut bacteria
and subsequently alter the gut microbiota composition in a
way that is beneficial to the host, resulting in the induction
of remission and/or the prevention of relapse. For example,
even in the absence of robust clinical evidence antibiotics
have been considered by some as an effective therapy in
IBD and routinely used as a therapeutic strategy. A diverse
group of antibiotics including macrolides, fluoroquinolones,
5-nitroimidazoles, rifaximin, and antimycobacterial therapy
either administered alone or in combination have been evaluated
in clinical trials for IBD treatment. In a meta-analysis antibiotics
were found to be superior to placebo (Khan et al., 2011). However,
the antibiotics had such a disparate spectrum of activity the
results of this meta analysis raises the question as to whether
it is important to attack a specific spectrum of organisms or
simply important to alter the gut microbiome in any way.
Antibiotic treatment for RA has been utilized without a firm
rationale as early as the 1930s with sulfasalazine, a combination of
sulphapyridine and 5-aminosalicylic acid (Svartz, 1948), and later
with tetracycline derivatives (Brown et al., 1971). A number of
clinical trials have evaluated the use of minocycline (Kloppenburg
et al., 1994; Tilley et al., 1995; O’Dell et al., 1997, 2001), macrolides
(Saviola et al., 2002, 2013; Ogrendik, 2007a, 2009; Ogrendik
and Karagoz, 2011) and levofloxacin (Ogrendik, 2007b) for
the treatment of RA. Evidence concerning therapeutic use of
antibiotics in MS is limited; use of minocycline for clinically
isolated syndrome and RRMS is currently in phase III of clinical
trials (Metz et al., 2009). There is currently no indication that
antibiotics are beneficial in SLE or most spondyloarthropathies.
Repopulating the gut with a healthy community is an
alternative approach to perturbing the existing microbiome,
but so far, outcomes from these methods are controversial
or not efficacious. Probiotics are dietary supplements that
contain live microorganisms that when administered are thought
to strengthen the existing gut microbiome. For IBD, the
efficacy of probiotics in clinical outcomes demonstrates variable
success. A recent meta-analysis of randomized controlled trials
evaluating the effectiveness of probiotics reported probiotic
supplementation is linked to inducing remission/response in
active UC but not CD (Shen et al., 2014). And, only VSL#3
(a combination of L. casei, L. plantarum, L. acidophilus, L.
delbruekii subsp. bulgaricus, B. longim, B. breve, B. infantis,
and S. salivarus subsp. thermophilus) significantly increased
remission/response rates. Studies indicate that probiotics cannot
treat CD and UC with equal effectiveness suggesting altering a
single parameter might not be enough to cure disease. There
is clinical evidence that probiotics (L. casei 01) as adjunctive
therapy improves disease activity and inflammatory status in
patients with RA (Vaghef-Mehrabany et al., 2014). In contrast,
a probiotic preparation containing S. salivarius, B. lactis, and
L. acidophilus demonstrated no significant benefit in patients
with spondyloarthritis (Jenks et al., 2010). There are currently no
published clinical trials to date of probiotic administration in MS
or SLE, though studies utilizing mice suggest a potential benefit
in both SLE (Alard et al., 2009) and MS (discussed above).
Prebiotic refers to a food substance that may be fermented
but not digested. The fermentation of prebiotics stimulates
growth and activity of gut microbes potentially benefiting the
host via production of energy and metabolic substrates. Studies
evaluating the clinical use of prebiotics in specific diseases
are limited, with the exception of CD. The administration of
15 g of fructo-oligosaccharides (inulin) in patients with active
ileocolonic CD has shown both promising results (Lindsay et al.,
2006) and no clinical benefit (Benjamin et al., 2011). A 10 g
lactulose administered to active CD patients demonstrated no
significant improvement (Hafer et al., 2007). Prebiotics may
be bloating and may in themselves lead to gastrointestinal
symptoms.
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Fecal microbiota transplantation (FMT) is another approach
that can be used in diseases linked to gut dysbiosis. FMT is
a novel technique in which the gut microbiota are transferred
from a healthy donor to the patient with the overall goal
to introduce a stable microbial community in the gut. Until
recently, FMT has primarily been utilized to successfully treat
recurrent antibiotic-resistant C. difficile infection (van Nood
et al., 2013). The clinical efficacy of FMT in UC is promising
as FMT has been shown to induce remission in a greater
percentage of patients than placebo and no difference in
adverse events were reported (Moayyedi et al., 2015). FMT
has been investigated in few other diseases including CD
(Gordon and Harbord, 2014; Quera et al., 2014) as case
reports, albeit data are too limited to determine clinical
usefulness. More randomized controlled trials are warranted
to evaluate donor selection and the frequency of FMT
administration.
CONCLUSION AND PERSPECTIVES
Immune-mediated inflammatory diseases are multifaceted
disorders that share many common underlying dynamics
including epidemiological co-occurrence, genetic susceptibility,
and numerous environmental factors. IMID are highly
influenced by the structural and functional characteristics of
the gut microbiome. Recent technological advancements have
facilitated comprehensive analyses through large cohort studies
and have expanded our knowledge of the structure and function
of the gut in health and in many diseases. Most available gut
microbiome research is correlative and experimental models
for testing hypotheses emergent from correlative associations
are necessary. Investigation of the microbiome and relevant
mechanisms poses a significant challenge because of the
complexity of the relationships between the microbiota with
host genetics and environmental factors. Nevertheless, many
microbiome surveys have focused on only a single IMID; future
microbiome studies should include multiple disease cohorts to
characterize the gut microbial populations simultaneously to
accurately examine how particular microbial groups are altered
between IMID.
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